Who owns KARYOPHARM THERAPEUTICS INC COM NEW?
- Ticker: KPTI
- CUSIP Number: 48576u205
Tip: Access positions for across all investors
Analyze quarterly positions in Karyopharm Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Karyopharm Therapeutics stock
Who bought or sold KARYOPHARM THERAPEUTICS INC COM NEW this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Ikarian Capital | 2.6M | $14M | 373% | Mar 2026 |
|
| Commodore Capital | 2.0M | $11M | 100% | Mar 2026 |
|
| RA Capital Management | 1.9M | $11M | 100% | Mar 2026 |
|
| T. Rowe Price Investment Management | 1.5M | $11M | 113% | Dec 2025 |
|
| Goldman Sachs Group | 948k | $5.3M | 100% | Mar 2026 |
|
| Catalio Capital Management | 898k | $5.0M | 528% | Mar 2026 |
|
| Affinity Asset Advisors | 890k | $6.5M | 464% | Dec 2025 |
|
| Susquehanna International | 835k | $6.1M | 196% | Dec 2025 |
|
| Boothbay Fund Management | 750k | $4.2M | 419% | Mar 2026 |
|
| Squadron Capital Management | 750k | $4.2M | 100% | Mar 2026 |
|
| Vanguard Capital Management | 740k | $4.1M | 100% | Mar 2026 |
|
| Jane Street | 594k | $3.3M | 550% | Mar 2026 |
|
| Vanguard Group | 560k | $4.1M | 37% | Dec 2025 |
|
| Millennium Management | 512k | $2.8M | 100% | Mar 2026 |
|
| Citadel Advisors | 508k | $2.8M | 275% | Mar 2026 |
|
| Avidity Partners Management | 464k | $2.6M | 245% | Mar 2026 |
|
| Soleus Capital Management | 440k | $2.5M | 0% | Mar 2026 |
|
| Adage Capital Partners GP | 421k | $3.1M | 0% | Dec 2025 |
|
| ADAR1 Capital Management | 342k | $1.9M | 584% | Mar 2026 |
|
| Davidson Kempner Capital Management | 300k | $1.7M | -3% | Mar 2026 |
|
| Exome Asset Management | 296k | $2.2M | 100% | Dec 2025 |
|
| Trexquant Investment | 258k | $1.4M | 518% | Mar 2026 |
|
| Boxer Capital Management | 253k | $1.9M | 100% | Dec 2025 |
|
| Ally Bridge Group | 250k | $1.4M | 100% | Mar 2026 |
|
| Acadian Asset Management | 249k | $1.4M | 6582% | Mar 2026 |
|
| BlackRock | 245k | $1.4M | -1% | Mar 2026 |
|
| Brevan Howard Capital Management | 212k | $1.2M | 100% | Mar 2026 |
|
| Geode Capital Management | 206k | $1.1M | 10% | Mar 2026 |
|
| UBS Group | 194k | $1.1M | 119% | Mar 2026 |
|
| Group One Trading | 192k | $1.1M | 87% | Mar 2026 |
|
| Balyasny Asset Management | 171k | $951k | 100% | Mar 2026 |
|
| Silverback Asset Management | 165k | $919k | 312% | Mar 2026 |
|
| Two Sigma Investments | 151k | $842k | 2% | Mar 2026 |
|
| Marshall Wace | 129k | $945k | 0% | Dec 2025 |
|
| Vanguard Fiduciary Trust | 115k | $640k | 100% | Mar 2026 |
|
| Polygon Management | 103k | $574k | 100% | Mar 2026 |
|
| CAM Group Holding A/S | 100k | $557k | 0% | Mar 2026 |
|
| Connor, Clark & Lunn Investment Management | 79k | $441k | 38% | Mar 2026 |
|
| Bridgeway Capital Management | 66k | $485k | 89% | Dec 2025 |
|
| Royal Bank of Canada | 60k | $334k | 797% | Mar 2026 |
|
| Renaissance Technologies | 60k | $441k | -7% | Dec 2025 |
|
| Quadrature Capital | 60k | $440k | 100% | Dec 2025 |
|
| State Street Corporation | 59k | $434k | 27% | Dec 2025 |
|
| Jump Financial | 54k | $397k | 100% | Dec 2025 |
|
| DAFNA Capital Management | 46k | $255k | -10% | Mar 2026 |
|
| Zimmer Partners | 38k | $209k | 100% | Mar 2026 |
|
| Centiva Capital | 34k | $188k | 100% | Mar 2026 |
|
| Simplex Trading | 33k | $242k | 461% | Dec 2025 |
|
| China Universal Asset Management | 30k | $167k | 100% | Mar 2026 |
|
| Point72 Asset Management | 30k | $167k | 100% | Mar 2026 |
|
| Northern Trust | 29k | $214k | 54% | Dec 2025 |
|
| Springbok Capital Management | 29k | $211k | 100% | Dec 2025 |
|
| Baird Financial | 28k | $206k | 8% | Dec 2025 |
|
| Bank of America Corporation | 20k | $109k | 100% | Mar 2026 |
|
| OMERS Administration Corporation | 19k | $108k | 100% | Mar 2026 |
|
| Morgan Stanley | 19k | $104k | 110% | Mar 2026 |
|
| Invesco | 17k | $93k | 100% | Mar 2026 |
|
| XTX Topco | 12k | $88k | -17% | Dec 2025 |
|
| Hsbc Holdings | 12k | $66k | 100% | Mar 2026 |
|
| Bank of New York Mellon | 11k | $64k | 3% | Mar 2026 |
|
| Vanguard Global Advisers | 8.2k | $46k | 100% | Mar 2026 |
|
| Citigroup | 4.9k | $28k | 100% | Mar 2026 |
|
| Barclays | 4.1k | $30k | 0% | Dec 2025 |
|
| TD Waterhouse Canada | 3.2k | $19k | 0% | Mar 2026 |
|
| Rockefeller Capital Management | 733.00 | $4.1k | 0% | Mar 2026 |
|
| FMR | 679.00 | $5.0k | 0% | Dec 2025 |
|
| Persistent Asset Partners | 610.00 | $226.615000 | -97% | Mar 2026 |
|
| Harbour Investments | 285.00 | $1.6k | 235% | Mar 2026 |
|
| Advisor Group Holdings | 282.00 | $2.1k | -18% | Dec 2025 |
|
| Quent Capital | 235.00 | $1.3k | 0% | Mar 2026 |
|
| Mb, Levis & Associates | 100.00 | $557.000000 | 0% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 84.00 | $467.997600 | 2% | Mar 2026 |
|
| SBI Securities | 67.00 | $373.002400 | -9% | Mar 2026 |
|
| Activest Wealth Management | 66.00 | $368.002800 | 0% | Mar 2026 |
|
| Hanson McClain Advisors | 26.00 | $191.999600 | 0% | Dec 2025 |
|
| West Branch Capital | 3.00 | $17.000100 | 0% | Mar 2026 |
|
| Atlantic Trust | 3.00 | $21.999900 | 0% | Dec 2025 |
|
Who sold out of Karyopharm Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Opaleye Management | Dec 2025 | 930k | $6.8M |
| Braidwell | Dec 2025 | 303k | $2.2M |
| Ameriprise Financial | Dec 2025 | 277k | $2.0M |
| Walleye Trading Advisors | Dec 2025 | 96k | $704k |
| Two Sigma Advisers | Dec 2025 | 90k | $660k |
| Context Capital Management | Dec 2025 | 63k | $464k |
| Tudor Investment Corporation | Dec 2025 | 13k | $95k |
| Belvedere Trading | Dec 2025 | 12k | $91k |
| CI Private Wealth | Dec 2025 | 10k | $10k |
| Tower Research Capital | Sep 2025 | 1.1k | $7.1k |
| Jpmorgan Chase & Co | Sep 2025 | 550.00 | $3.6k |
| Aspect Partners | Dec 2025 | 391.00 | $2.9k |
| Advisory Services Network | Sep 2025 | 12.00 | $78.000000 |